Latest papers

[Functional outcome in schizophrenia: relation to the MATRICS consensus cognitive battery].

Morbidity and mortality in schizophrenia.

[PolyI:C-induced neurodevelopmental animal model for schizophrenia].

[Neuronal development of the hyperdopaminergic animal model].

[Schizophrenia Cognition Rating Scale Japanese version (SCoRS-J) as a co-primary measure assessing cognitive function in schizophrenia].

[Does cannabis use lead to schizophrenia?].

Lurasidone: a new treatment option for schizophrenia.

Cognitive therapy may aid patients with schizophrenia.

Psychiatric co-morbidity with type 1 and type 2 diabetes mellitus.

Eye movement during facial affect recognition by patients with schizophrenia, using Japanese pictures of facial affect.

Theory of mind in schizophrenia: exploring neural mechanisms of belief attribution.

The role of energy metabolism dysfunction and oxidative stress in schizophrenia revealed by proteomics.

[Old patients suffering from long-standing schizophrenia: clinical aspects].

Facts and visions. Abstracts of the 3rd European Conference on Schizophrenia Research. September 29-October 1, 2011. Berlin. Germany.

Long-acting risperidone and oral antipsychotics in schizophrenia.

Long-acting risperidone and oral antipsychotics in schizophrenia.

Regulation of immune-modulatory genes in left superior temporal cortex of schizophrenia patients: a genome-wide microarray study.

Schizophrenia: Zooming in on a gene.

Genetics in psychiatry: are the promises met?

Abstracts of the 13th International Congress on Schizophrenia Research (ICOSR). April 2-6, 2011. Colorado Springs, Colorado, USA.